Protalix BioTherapeutics (PLX) Smacked On UBS Intra-Day Downgrade
Tweet Send to a FriendGet Alerts PLX Hot Sheet
Price: $5.23 +0.38%
Rating Summary:
2 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 24 | New: 29
Rating Summary:
2 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 24 | New: 29
Trade PLX Now!
An intra-day downgrade pushed shares of Protalix BioTherapeutics, Inc. (NYSE: PLX) down over 5%, although the stocks is now recovering into the close - currently down 3%.
UBS downgraded shares from Buy to Neutral and cut their price target from $11 to $10. Analyst Christopher Schaefer said, "we believe upside from current levels is limited based on fundamentals." The current price reflects the approval, he stated.
Although UBS still expects FDA approval by the Feb 25th PDUFA date, the firm has re-examined their Gaucher disease market assumptions. UBS now forecast 2015E taliglucerase alfa revenues of $52.3m in the US, $208.6m ROW (excluding Israel) and $45.7m in Israel.
In addition to U.S. approval, UBS expects Israeli approval shortly after and EU and Brazilian approval in 3Q11.
UBS mentioned a draft version of the taliglucerase label was posted on the Brazilian Ministry of Health website, which contains a black box warning and it further characterized the hypersensitivity reactions observed in the pivotal trial as anaphylactoid reactions. "According to PLX, this was an old version used for the expanded access program and its current regulatory submissions contain a different version that is very similar to Cerezyme's. If a black box is included in the final label, we see downside risk to the shares," Schaefer notes.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
UBS downgraded shares from Buy to Neutral and cut their price target from $11 to $10. Analyst Christopher Schaefer said, "we believe upside from current levels is limited based on fundamentals." The current price reflects the approval, he stated.
Although UBS still expects FDA approval by the Feb 25th PDUFA date, the firm has re-examined their Gaucher disease market assumptions. UBS now forecast 2015E taliglucerase alfa revenues of $52.3m in the US, $208.6m ROW (excluding Israel) and $45.7m in Israel.
In addition to U.S. approval, UBS expects Israeli approval shortly after and EU and Brazilian approval in 3Q11.
UBS mentioned a draft version of the taliglucerase label was posted on the Brazilian Ministry of Health website, which contains a black box warning and it further characterized the hypersensitivity reactions observed in the pivotal trial as anaphylactoid reactions. "According to PLX, this was an old version used for the expanded access program and its current regulatory submissions contain a different version that is very similar to Cerezyme's. If a black box is included in the final label, we see downside risk to the shares," Schaefer notes.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: JPMorgan Cuts SodaStream (SODA) to Neutral, 'Stock No Longer Cheap'
- Goldman Sachs Downgrades InterXion Holding (INXN) to Neutral
- UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'
Create E-mail Alert Related Categories
Downgrades, Hot Downgrades, Insiders' BlogRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
